Literature DB >> 31112940

Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.

Zhihong Zeng1, Wenbin Liu2, Christopher B Benton1, Sergej Konoplev3, Hongbo Lu1, Rui-Yu Wang1, Julianne Chen4, Elizabeth Shpall4, Keith A Baggerly2, Richard Champlin4, Marina Konopleva5,6.   

Abstract

To characterize intracellular signaling in peripheral blood (PB) cells of acute myeloid leukemia (AML) patients undergoing pretransplant conditioning with CXCR4 inhibitor plerixafor, granulocyte colony-stimulating factor (G-CSF), and busulfan plus fludarabine (Bu+Flu) chemotherapy, we profiled 153 proteins in 33 functional groups using reverse phase protein array. CXCR4 inhibition mobilized AML progenitors and clonal AML cells, and this was associated with molecular markers of cell cycle progression. G-CSF/plerixafor and G-CSF/plerixafor/Bu+Flu modulated distinct signaling networks in AML blasts of patients undergoing conditioning with active disease compared to nonleukemic PB cells of patients in remission. We identified AML-specific proteins that remained aberrantly expressed after chemotherapy, representing putative chemoresistance markers in AML.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Acute myeloid leukemia; Allogeneic stem cell transplantation; CXCR4; Plerixafor; Proteomic profiling of signaling

Mesh:

Substances:

Year:  2019        PMID: 31112940      PMCID: PMC6792289          DOI: 10.1159/000495456

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  23 in total

Review 1.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

2.  Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.

Authors:  Raymond Wong; Munir Shahjahan; Xuemei Wang; Peter F Thall; Marcos De Lima; Issa Khouri; James Gajewski; Jorge Alamo; Daniel Couriel; Borje S Andersson; Michelle Donato; Chitra Hosing; Krishna Komanduri; Paolo Anderlini; Jeffrey Molldrem; Naoto T Ueno; Elihu Estey; Cindy Ippoliti; Richard Champlin; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2005-02       Impact factor: 5.742

3.  Proliferating cell nuclear antigen acts as a cytoplasmic platform controlling human neutrophil survival.

Authors:  Véronique Witko-Sarsat; Julie Mocek; Dikra Bouayad; Nicola Tamassia; Jean-Antoine Ribeil; Céline Candalh; Noélie Davezac; Nathalie Reuter; Luc Mouthon; Olivier Hermine; Magali Pederzoli-Ribeil; Marco A Cassatella
Journal:  J Exp Med       Date:  2010-10-25       Impact factor: 14.307

4.  A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.

Authors:  H C Fung; A Stein; M l Slovak; M R O'donnell; D S Snyder; S Cohen; D Smith; A Krishnan; R Spielberger; R Bhatia; S Bhatia; P Falk; A Molina; A Nademanee; P Parker; R Rodriguez; J Rosenthal; R Sweetman; N Kogut; F Sahebi; L Popplewell; N Vora; G Somlo; K Margolin; W Chow; E Smith; S J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2003-12       Impact factor: 5.742

5.  Functional proteomic profiling of AML predicts response and survival.

Authors:  Steven M Kornblau; Raoul Tibes; Yi Hua Qiu; Wenjing Chen; Hagop M Kantarjian; Michael Andreeff; Kevin R Coombes; Gordon B Mills
Journal:  Blood       Date:  2008-10-07       Impact factor: 22.113

6.  The stromal cell-derived factor-1alpha dependent migration of human cord blood CD34 haematopoietic stem and progenitor cells switches from protein kinase C (PKC)-alpha dependence to PKC-alpha independence upon prolonged culture in the presence of Flt3-ligand and interleukin-6.

Authors:  Benjamin Kasenda; Susannah H Kassmer; Bernd Niggemann; Sven Schiermeier; Wolfgang Hatzmann; Kurt S Zänker; Thomas Dittmar
Journal:  Br J Haematol       Date:  2008-06-05       Impact factor: 6.998

7.  Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

Authors:  John F DiPersio; Edward A Stadtmauer; Auayporn Nademanee; Ivana N M Micallef; Patrick J Stiff; Jonathan L Kaufman; Richard T Maziarz; Chitra Hosing; Stefan Früehauf; Mitchell Horwitz; Dennis Cooper; Gary Bridger; Gary Calandra
Journal:  Blood       Date:  2009-04-10       Impact factor: 22.113

8.  GSK3 Deficiencies in Hematopoietic Stem Cells Initiate Pre-neoplastic State that Is Predictive of Clinical Outcomes of Human Acute Leukemia.

Authors:  Borhane Guezguez; Mohammed Almakadi; Yannick D Benoit; Zoya Shapovalova; Susann Rahmig; Aline Fiebig-Comyn; Fanny L Casado; Borko Tanasijevic; Silvia Bresolin; Riccardo Masetti; Bradley W Doble; Mickie Bhatia
Journal:  Cancer Cell       Date:  2016-01-11       Impact factor: 31.743

9.  A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.

Authors:  G L Uy; M P Rettig; R M Stone; M Y Konopleva; M Andreeff; K McFarland; W Shannon; T R Fletcher; T Reineck; W Eades; K Stockerl-Goldstein; C N Abboud; M A Jacoby; P Westervelt; J F DiPersio
Journal:  Blood Cancer J       Date:  2017-03-10       Impact factor: 11.037

Review 10.  Taking a Bad Turn: Compromised DNA Damage Response in Leukemia.

Authors:  Nadine Nilles; Birthe Fahrenkrog
Journal:  Cells       Date:  2017-05-04       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.